Sort
10,766 grants matching “checkpoint inhibitor”
Molecular Determinants of Chromosome Transmission and Cell Cycle Regulation
$1,635,259Munira Basrai · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous model
$1,632,775Grace Elizabeth Pluhar · University Of Minnesota · U01 · FY2017 · CA
Prospective validation of a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy
$1,625,000Petr Jordan · Onc.Ai, Inc. · R44 · FY2024 · CA
Pathway inhibitors in Lymphomas
$1,616,572Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Studies of Childhood Solid Tumors
$1,604,058St. Jude Children'S Research Hospital · P01 · FY2004 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$1,603,147Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Computational methods for multiplex image analysis of the tumor microenvironment
$1,602,000William Edward Lotter · Dana-Farber Cancer Inst · R01 · FY2025 · LM
Modification of hyperthermia response
$1,599,381Dennis B Leeper · Thomas Jefferson University · P01 · FY2006 · CA
Canine Immuno Neurotherapeutics
$1,596,668M R Chambers · University Of Alabama At Birmingham · U01 · FY2017 · CA
Modification of hyperthermia response
$1,594,884Thomas Jefferson University · P01 · FY2005 · CA
Strategies for Cancer Immunotherapy Clinical Trials
$1,593,930Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
ART Modulation of Viral Pathogenesis
$1,579,497Dirk P Dittmer · Univ Of North Carolina Chapel Hill · R01 · FY2025 · DE
Clinical and Mechanistic Investigations of Salivary Gland Dysfunction
$1,577,200Blake Warner · National Institute Of Dental & Craniofacial Research · ZIA · FY2022 · DE
CD28-KITv CAR T cells with PD-1 dominant negative receptor
$1,570,342Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · UG3 · FY2025 · CA
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
$1,566,249Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2022 · CA
Strategies for Cancer Immunotherapy Clinical Trials
$1,566,117Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,566,117Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Muscle Disease Unit
$1,560,838Andrew Mammen · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2023 · AR
Human Artificial Chromosomes for Cancer Research and Functional Genomics
$1,560,660Vladimir Larionov · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
$1,558,904Angelo Michael De Marzo · Johns Hopkins University · U54 · FY2022 · CA
Studies of Childhood Solid Tumors
$1,558,131St. Jude Children'S Research Hospital · P01 · FY2003 · CA
Muscle Disease Unit
$1,557,664Andrew Mammen · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2018 · AR
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,555,914Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2023 · CA
Studies of Childhood Solid Tumors
$1,554,855St. Jude Children'S Research Hospital · P01 · FY2002 · CA
Advanced therapeutic for Parkinson's Disease
$1,554,563Milton H. Werner · Inhibikase Therapeutics · R44 · FY2018 · NS